All stock lists
Ping An Biomedical Co., Ltd. (NASDAQ:PASW)
HK · Delayed Price · Currency is USD
Industrials · Manufacturing - Textiles
1.79-1.14 (-38.74%)
Market cap
$5.61M
Insider Score
Health Score
Listed since
Jul 18, 2025
Website
Insider Score
––Not scored
PASW Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From PASW’s reported statements · Q1 2026 (trailing 12 months)
Profitability3 / 20
Loses money on what it sells.
- Revenue
- $25.5M
- Net income
- -$3.8M
- Net margin
- -14.8%
Leverage19 / 20
Little or no net debt.
- Total debt
- $10.3M
- Cash
- $6.8M
- Debt / equity
- 0.13
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $55.9M
- Current liabilities
- $22.0M
- Current ratio
- 2.54
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$5.5M
- Free cash flow
- -$5.5M
- FCF margin
- -21.7%
Dilution & runway0 / 20
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 1.3M
- Share growth (1y)
- 180.7%
- Cash runway
- 15 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
PASW Income Statement
| Fiscal Period | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Period Ending | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 |
| Revenue | 4.80 M | 4.80 M | 7.96 M | 7.96 M | 9.12 M | 9.12 M |
| Revenue Growth (YoY) | -47.37 % | -47.37 % | — | — | — | — |
| Cost of Revenue | 4.44 M | 4.44 M | 7.14 M | 7.14 M | 9.46 M | 9.46 M |
| Gross Profit | 361.68 K | 361.68 K | 820.91 K | 820.91 K | -346.16 K | -346.16 K |
| SG&A Expense | 92.88 K | 92.88 K | 6.36 M | 6.36 M | 1.46 M | 1.46 M |
| R&D Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 92.88 K | 92.88 K | 6.36 M | 6.36 M | 1.46 M | 1.46 M |
| Operating Income | 268.80 K | 268.80 K | -5.54 M | -5.54 M | -1.81 M | -1.81 M |
| Pretax Income | 3.14 M | 3.14 M | -5.47 M | -5.47 M | -1.87 M | -1.87 M |
| Tax Provision | 728.87 K | 728.87 K | 1.18 M | 1.18 M | 247.44 K | 247.44 K |
| Net Income | 2.41 M | 2.41 M | -4.30 M | -4.30 M | -2.12 M | -2.12 M |
| EPS (Basic) | 1.91 | 1.91 | -9.20 | -9.20 | -4.80 | -4.80 |
| EPS (Diluted) | 1.91 | 1.91 | -9.20 | -9.20 | -4.80 | -4.80 |
| Shares Outstanding | 1.26 M | 1.26 M | 473.97 K | 473.97 K | 450.00 K | 450.00 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.